This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: Researchers at the Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University have developed a way to observe how antibodies interact with a cancer-related protein carried on tiny membrane-bound vesicles released by cells. Using high-speed atomic force microscopy, they found that measuring how much of the protein is present does not necessarily show how accessible it is to antibodies.
The findings reported in the journal Small Methods provide a new way to investigate differences between individual cancer-derived vesicles although further research is needed before the approach can be used clinically. Cancer cells can avoid attack by the immune system in several ways. One involves a protein called programmed death-ligand 1, or PD-L1.
When PD-L1 interacts with immune cells, it can act as a brake that reduces their ability to attack a tumor. Medicines that block this interaction have transformed the treatment of some cancers, but patients respond very differently. Tests often measure how much PD-L1 is present.
However, quantity is only part of the picture. A protein may be present but partly hidden by nearby molecules or positioned in a way that makes it difficult for an antibody to reach. This physical availability is known as accessibility.
The Kanazawa University team investigated PD-L1 on small extracellular vesicles. These are tiny membrane-bound packages released by cells that carry proteins and other biological material. They can travel between cells and help cells communicate.
Vesicles released by tumors can also influence immune responses. Their surfaces vary from one vesicle to another, so measurements made across large groups can conceal important differences. Reon Imakawa and colleagues led by Richard W.
Extract — continue reading at the source.
